Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Nutriband Inc.NASDAQ: NTRB

Gross Margin · Q1 FY2026 · quarter ended Apr 2026

Gross margin widens to 45.4%

Gross margin was 45.4% in Q1 FY2026, up 7.7 pp from a year earlier. On a trailing-twelve-month basis it was 28.4%, down 4.9 pp year over year. Over 3 fiscal years it narrowed by 8.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
45.4%+23.2 pp QoQ
Last fiscal yearJan 2026
27.8%-4.9 pp YoY
LTMApr 2026
28.4%-4.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.7 pp——
1 year-4.9 pp——
3 years-8.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
27.8%
Year-over-year change
-4.9pp

Gross Margin vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 gross margin of 28.4% is the 3rd highest of the 4 companies compared; the peer median is 64.5%.
  • Its year-over-year change of -4.9 pp is the 2nd highest of 3, against a peer median of -2.1 pp.
  • Over three fiscal years its change of -8.3 pp compares with a peer median of +0.0 pp.
NTRB Competitors Peer median
Gross Margin for NTRB and competitors
Company Period LTM level YoY 3-year change
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
NTRBNutriband Inc.LTM Apr 202628.4% -4.9 pp-8.3 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
XBITXBiotech Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding NTRB) 64.5%-2.1 pp+0.0 pp

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.